Table 2.
HIV-related Characteristics of HIV-infected Men
| HIV-infected Men |
|||||
|---|---|---|---|---|---|
| All | Age-Restricted (33-45 years)* |
||||
| n | 737 | 390 | |||
| HIV Risk Factors | Heterosexual | 10% | 10% | ||
| IDU | 17% | 14% | |||
| MSM | 67% | 70% | |||
| Other | 7% | 5% | |||
| Duration HIV (y) | Median (IQR) | 8.0 (5.0-12.0) | 8.0 (5.2-12.0) | ||
| HIV RNA (1000/mL) | Median (IQR) | 0.4 (0.4-13.2) | 0.4 (0.4-9.4) | ||
| CD4 (cells/uL) | Median (IQR) | 339 (219-520) | 358 (230-517) | ||
| Current ARV Use and Duration (years): | % | Median (IQR) | % | Median (IQR) | |
| HAART | 80% | 3.0 (1.6-4.4) | 82% | 2.9 (1.7-4.4) | |
| NRTI | 87% | 4.1 (2.3-5.6) | 88% | 4.0 (2.3-5.4) | |
| NNRTI | 41% | 1.5 (0.8-2.2) | 39% | 1.5 (0.8-2.1) | |
| PI | 57% | 3.1 (1.6-4.4) | 60% | 3.0 (1.8-4.4) | |
| Lamivudine | 63% | 3.1 (1.5-4.5) | 62% | 3.0 (1.6-4.4) | |
| Stavudine | 44% | 3.0 (1.4-4.2) | 43% | 2.9 (1.4-4.1) | |
| Abacavir | 20% | 1.2 (0.6-2.1) | 22% | 1.1 (0.6-2.0) | |
| Didanosine | 17% | 1.8 (0.7-2.9) | 18% | 1.9 (0.7-2.9) | |
| Zalcitabine | 1% | 2.9 (1.3-4.5) | 1% | 3.3 (1.7-5.0) | |
| Zidovudine | 31% | 2.7 (1.2-4.3) | 33% | 2.6 (1.3-4.1) | |
| Ritonavir | 29% | 1.1 (0.5-2.4) | 33% | 1.3 (0.6-2.5) | |
| Indinavir | 18% | 3.1 (1.8-4.5) | 16% | 3.1 (1.8-4.5) | |
| Nelfinavir | 17% | 2.5 (1.6-3.7) | 16% | 2.7 (2.0-3.5) | |
| Lopinavir | 12% | 0.5 (0.2-0.8) | 13% | 0.5 (0.1-0.9) | |
| Saquinavir | 10% | 2.5 (1.6-3.7) | 13% | 2.5 (1.5-3.6) | |
| Amprenavir | 6% | 1.0 (0.5-1.4) | 7% | 1.0 (0.2-1.4) | |
| Efavirenz | 28% | 1.4 (0.7-2.1) | 25% | 1.5 (0.7-2.1) | |
| Nevirapine | 12% | 1.6 (0.8-2.4) | 13% | 1.2 (0.7-2.0) | |
| Delavirdine | 1% | 1.2 (0.4-2.1) | 1% | 1.7 (0.3-3.3) | |
| Ritonavir Dose | >400 mg/day | 7% | 9% | ||
| ≤400 mg/day | 23% | 24% | |||
| None | 70% | 67% | |||
Excluding all participants with recent opportunistic infections
*
HIV-infected participants were restricted to those in the age range of controls.
Abbreviations: IQR = interquartile range.